Iterative Health Appoints Dr. Nadege Gunn as Chief Medical Officer for Hepatology and Obesity
Nadege Gunn, MD, Chief Medical Officer, Hepatology and Obesity, Iterative Health • Photo Credit: Iterative Health
CAMBRIDGE, Mass., February 15, 2026 (WELLNESS INTERVIEWS) — Healthcare technology and services company Iterative Health has announced the appointment of Nadege Gunn, MD, as Chief Medical Officer, Hepatology and Obesity.
Wellness Interviews
♾️
Wellness Interviews ♾️
Dr. Gunn joins the senior leadership team to provide strategic medical and scientific leadership across metabolic liver disease research and specialized site operations, supporting the company’s hepatology and obesity portfolio. She will oversee medical affairs, development of specialized site operations, and collaboration with biopharmaceutical sponsors and contract research organization partners.
Dr. Gunn is a board-certified gastroenterologist, hepatologist, obesity medicine specialist, and physician-scientist with more than 15 years of experience as a principal investigator on over 100 early- and late-phase clinical trials. Her research experience includes metabolic liver disease, including MASH and MASLD. She currently practices at Coryell Health, where she serves as hepatology clinic director.
Gunn previously founded and served as President and CEO of Impact Research Institute in Waco, Texas. She has held academic teaching appointments at Texas A&M University, Dell Medical School at The University of Texas at Austin, and Baylor University. She also serves as a committee member of the Chronic Liver Disease Foundation’s Women in Hepatology: Initiatives, Sponsorship, and Empowerment (WHISE).
“Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale. As a practicing physician and with experience as a principal investigator, I’m excited to join a team that is deeply focused on empowering providers and extending cutting-edge clinical research into the communities that care for these patients every day,” said Dr. Gunn.
In addition to Gunn’s appointment, Iterative Health announced the promotion of Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. In the new role, Feuchtbaum will oversee operations and technology development across the company’s global site network spanning four continents.
“For providers and sponsors alike, Dr. Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support. Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale,” said Feuchtbaum, Chief Operating Officer at Iterative Health.
Iterative Health is headquartered in Cambridge, Massachusetts, and New York, New York, and combines clinical trial expertise with artificial intelligence to support research teams and study sponsors.
For more information, visit www.iterative.health.
Source: Iterative Health
